首页 | 本学科首页   官方微博 | 高级检索  
     


FLT3 inhibitors in acute myeloid leukemia
Authors:Mei Wu  Chuntuan Li  Xiongpeng Zhu
Affiliation:1.Department of Hematology,The People’s Hospital of Bozhou,Bozhou,China;2.Department of Hematology,First Hospital of Quanzhou affiliated to Fujian Medical University,Quanzhou,China
Abstract:FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号